triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
== Case against Stephen Dank == The AFL Tribunal heard cases against sports scientist Stephen Dank during the summer of 2014/15, and he was found guilty of ten charges. The charges upheld against Dank covered a wide range of illegal supplements that he trafficked in, attempted to traffic in, or was complicit in attempted trafficking when the AFL registered him. The upheld charges were:
Deliriants atropine (alkaloid found in plants of the family Solanaceae, including datura, deadly nightshade, henbane and mandrake) dimenhydrinate (Dramamine, an antihistamine) diphenhydramine (Benadryl, Unisom, Nytol) hyoscyamine (alkaloid also found in the Solanaceae) hyoscine hydrobromide (another Solanaceae alkaloid) myristicin (found in Myristica fragrans ("Nutmeg")) ibotenic acid (found in Amanita muscaria ("Fly Agaric"); prodrug to muscimol) muscimol (also found in Amanita muscaria, a GABAergic) Dissociatives dextromethorphan (DXM; Robitussin, Delsym, etc.; "Dex", "Robo", "Cough Syrup", "DXM") "Triple C's, Coricidin, Skittles" refer to a potentially fatal formulation containing both dextromethorphan and chlorpheniramine.
where subscripts p and n stand for the proton and neutron, and g(l)n = 0. By using the same identities as here and using the value g(l)p = 1, one gets the following result, in units of the nuclear magneton μN
Sources: en.wikipedia.org
One of the earliest systematic attempts of modern nation-states to implement border controls to restrict the entry of particular groups was the policy adopted by Canada, Australia, and America to curtail the immigration of Asians in white settler states in the late 19th and early 20th centuries. The first anti-East Asian policy implemented in this era was the Chinese Exclusion Act of 1882 in America, which was followed by the Chinese Immigration Act of 1885 in Canada, which imposed what came to be called the Chinese head tax. These policies were a sign of injustice and unfair treatment to the Chinese workers because the jobs they engaged in were mostly menial. Similar policies were adopted in various British colonies in Australia over the latter half of the 19th century targeting Asian immigrants arriving as a result of the region's series of gold rushes as well as Kanakas (Pacific Islanders brought into Australia as indentured labourers) who alongside the Asians were perceived by trade unionists and White blue collar workers as a threat to the wages of White settlers. Following the establishment of the Commonwealth of Australia in 1901, these discriminatory border control measures quickly expanded into the White Australia Policy, while subsequent legislation in America (e.g. the Immigration Act of 1891, the Naturalisation Act of 1906, the Immigration Act of 1917, and the Immigration Act of 1924) resulted in an even stricter policy targeting immigrants from both Asia and parts of southern and eastern Europe.
nucleosome-depleted region (NDR) A region of a genome or chromosome in which long segments of DNA are bound by few or no nucleosomes, and thus exposed to manipulation by other proteins and molecules, especially implying that the region is transcriptionally active.
In the context of the fall of communism throughout Eastern Europe during the revolutions of 1989, a protest in support of Reformed pastor László Tőkés that began in December 1989 in Timișoara quickly escalated into a national uprising against the communist regime, ultimately resulting in the execution of Ceaușescu and his wife Elena on 25 December 1989. An interim council composed of figures from civil society and former communist officials assumed control of the government, and Ion Iliescu became the provisional president of the country. The new government reversed many of the authoritarian communist policies and dismissed several leaders of the former regime, although still influenced by members of the former regime (the basis for the Golaniad, and Mineriads). In May 1990, the first free elections in Romania since the 1937 elections were held, with Iliescu of the National Salvation Front winning the presidency with 85% of the vote. In 1992, he was reelected in the first election after the adoption of a permanent constitution via a referendum held the previous year. Illiescu lost the 1996 election to Emil Constantinescu, but returned to power in 2000. Traian Băsescu was elected president in 2004 and 2009, serving until 2014 at which point Klaus Iohannis succeeded him, being re-elected in 2019 and serving until 2025. During these years several events occurred. In 2009, the country was bailed out by the International Monetary Fund as result of the Great Recession in Europe following the 2008 financial crisis.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.